Pharmaceutical In House Sales Presentation ZD686676
This is a value proposition video being made to communicate to a pharmaceutical company sales force. It is meant to explain to the sales team how to best present a newly-researched drug product.
The product is not being advertised to users--rather, we are explaining its benefits to a sales force. That being said, this product presents a new treatment for a population of elderly and very ill patients, so there should be a little bit of warmth in the delivery.
This script is technical at times and requires pronunciation of non-standard words. Pronunciation is very important, and we may ask you to re-record to get the correct inflection. Here are some of the pronunciations, and I will provide a sound file of pronunciations if needed: Venetoclax: Vuh-NET-uh-klax R/R: RR del(17p): Del seventeen p (N=107): En equals one-oh-seven ibrutinib: ih-BRUTE-uh-nib idelalisib: eye-duh-LAL-uh-sib lysis: LIE-sis
This is a very quick turnaround project which needs to be completed on Tuesday, April 5.
2016-04-01 22:44:22 GMT
2016-04-03 12:00:00 (GMT -06:00) Central Time (US & Canada)
Yes (click here to learn more about )
Closed15150 direct invitation(s) have been sent by the voice seeker resulting in 0 audition(s) and/or proposal(s) so far.
Voice123 SmartCast is seeking 30 auditions and/or proposals for this project (approx.) Invitations sent by SmartCast have resulted in 15 audition(s) and/or proposal(s) so far.
The Voice Actor should be located in:
Fixed - USD 200
Training, business presentations, sales, and web sites
English - USA and Canada
Middle Age Female
• Audio files must be delivered via email OR • Audio files must be delivered via FTP/Dropbox/Google Drive/cloud
There are no special pre-, post-, or production requirements for this project.
This is a non-union project
In a phase 2 study of R/R del(17p), CLL (N=107), venetoclax has been proven to be highly effective with an overall response rate of 79.4%, with 7.5% of patients experiencing complete remission, and 17% of patients achieving MRD-negative status. At 12 months follow-up, greater than 70 % of the patients had not progressed and 85% are still alive. Preliminary results also show efficacy with venetoclax in the difficult-to-treat CLL patient population that has relapsed or is refractory to multiple treatments including ibrutinib or idelalisib, demonstrated a 61% and 50% respectively, overall response with venetoclax.
Please note that you should only use the script or your recording of it for auditioning purposes. The script is property, unless otherwise specified, of the voice seeker and it is protected by international copyright laws.
80539Sign in to display the company name (if applicable)2012-04-125 7
Voice123 Team Comments
Voice123 consultations with this voice seeker regarding this project and/or other projects by this voice seeker, via phone,
chat, and/or email.
This project - phone.
Previous projects - phone.
This project - email or chat.
Previous projects - email or chat.
Corporate web site for this voice-seeker confirmed by Voice123
Note: Voice123 strives to establish the legitimacy of all projects posted. However, Voice123 subscribers and users are responsible for confirming information stated by prospective voice seekers, agents and/or clients. Voice123 subscribers and users assume all liability for use of any information found through Voice123, or any of its publications.
This page contains the most important details of this project. If you find the information on this project inaccurate or inappropriate, please let us know by contacting us.
Paste this link in an email to a friend, IM or other website